Mar 8, 2021
High-dose, accelerated radiotherapy brings better 2-year overall survival, with no added toxicity
In patients with limited stage, small-cell lung cancer (SCLC), hyperfractionated, accelerated, twice-daily thoracic radiotherapy (60 Gy) was feasible, and higher doses brought about significant improvements in two-year and median overall survival compared with the standard dose and schedule (45 Gy), with no additional toxicities, according to a study published in
“To our knowledge, the two-year overall survival in our trial is the highest reported in trials in limited stage SCLC, including all trials of high-dose, once-daily thoracic radiotherapy, and adds to the evidence suggesting that accelerated, hyperfractionated thoracic radiotherapy is the most effective approach in this disease,” wrote Bjørn Henning Grønberg, MD, of the Norwegian University of Science and Technology, Trondheim, Norway, and colleagues.
A Patient Insisted on a Trial Docs Listened and Saved Lives
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
CAR T-cell Products Shine, Reveal New Insights
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.